Revolution Medicines, Inc.
$43.36B- Market cap
- $45.01B
- Debt
- +$193.93M
- Cash
- −$1.85B
Capital structure 100% equity / 0% debt · EV / Revenue 3744.03x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: RVMD stock price at premium vs SNN $210.02 current versus $0.11 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SNN's multiple
Implied fair value · at RVMD's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: RVMD FY 2023 (ended Dec 31, 2023) · SNN FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 100% equity / 0% debt · EV / Revenue 3744.03x
Capital structure 71% equity / 29% debt · EV / Revenue 2.80x · EV / EBITDA 22.54x
RVMD carries the larger enterprise value at $43.36B against $17.24B; SNN trades on the lower EV / Revenue multiple (2.80x vs 3744.03x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Revolution Medicines, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Smith & Nephew plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.11x
—
Net debt / EBITDA
Leverage against operating earnings
3.85x
5.98x
Cash and equivalents
Liquid reserves on the balance sheet
$1.85B
$557.00M
Total debt
Interest-bearing obligations outstanding
$193.93M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
RVMD vs AMGN
BRISTOL MYERS SQUIBB CO
RVMD vs BMY
GILEAD SCIENCES, INC.
RVMD vs GILD
INCYTE CORP
RVMD vs INCY
VERTEX PHARMACEUTICALS INC / MA
RVMD vs VRTX
Moderna, Inc.
RVMD vs MRNA
STRYKER CORP
RVMD vs SYK
CVS HEALTH Corp
RVMD vs CVS
JOHNSON & JOHNSON
RVMD vs JNJ
BOSTON SCIENTIFIC CORP
RVMD vs BSX
$5.13B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.